LIVE
NVCR
NovoCure Limited · Health Care - Medical Devices / Oncology
$14.28
-16.05% this month
VERSUS
⟷
COMPARE
BEAM
Beam Therapeutics Inc. · Health Care - Biotechnology / Gene Editing
$34.14
+29.66% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
NVCR
3
BEAM
1
Comparison scoreboard
NVCR LEADS 3/5AI Score
NVCR ✓34.0
BEAM 33.2
1Y Return
NVCR -15.00%
BEAM ✓+100.94%
Fwd P/E
NVCR ✓-11.97
BEAM -7.20
Target Up.
NVCR ✓+82.07%
BEAM +49.58%
Op. Margin
NVCR N/A
BEAM N/A
Metrics last refreshed: 6/20/2026
Quick take
NVCR vs BEAM Stock Comparison: AI Score, Valuation, Performance and Upside
NVCR is a commercial-stage medical device company generating revenue from its TTFields cancer therapy platform while pursuing clinical expansion into larger cancer markets, while BEAM is a preclinical/early-clinical gene editing biotech with no approved products but a promising precision editing technology. These represent different stages of biomedical innovation investment.
NVCR vs BEAM contrasts a commercial medical device company expanding its cancer therapy into new indications against a precision gene editing biotech pursuing curative therapies for genetic diseases, both representing frontier biomedical technologies.
Live analysis · updated 6/20/2026
NVCR holds the edge across 3 of 5 key metrics in this comparison. BEAM has delivered stronger 1-year price return (+100.94% vs -15.00%), though NVCR trades at the lower forward P/E (-11.97x vs -7.20x). Analyst consensus implies meaningfully more upside for NVCR (+82.07%) than for BEAM (+49.58%).
Normalized 1Y performance
NVCR
BEAM
Recent returns
NVCR
BEAM
Analyst price targets & sentiment
NVCR · 7 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.7/5.0)
Price target range
analyst low$17.00
analyst high$46.00
analyst mean$26.00
current price$14.28
+82.1% upside to analyst mean
BEAM · 15 analysts
STRONG BUYHOLDSTRONG SELL
Strong Buy (1.3/5.0)
Price target range
analyst low$26.00
analyst high$80.00
analyst mean$51.07
current price$34.14
+49.6% upside to analyst mean
Who should consider this stock?
NVCR may suit investors who:
- →Want commercial biomedical innovation exposure with existing revenue from approved GBM and mesothelioma indications
- →See the EF-32 lung cancer trial as a high-value clinical binary catalyst that could dramatically expand the addressable market
- →Value TTFields' additive mechanism as combining with existing cancer therapies rather than replacing them, reducing adoption hurdles
BEAM may suit investors who:
- →Want early-stage exposure to base editing gene therapy technology with potential for curative treatments in genetic diseases
- →Value Beam's proprietary base editing chemistry as a differentiated precision approach versus traditional CRISPR cutting
- →Are comfortable with clinical-stage biotechnology risk and long development timelines in exchange for potentially transformative disease-modifying therapy potential
Performance & AI score
| Metric | NVCR | BEAM |
|---|---|---|
| AI score | 34.0 | 33.2 |
| AI rank | #1808 | #1942 |
| Latest close | $14.28 | $34.14 |
| 1M return | -16.05% | +29.66% |
| 6M return | +15.82% | +33.36% |
| 1Y return | -15.00% | +100.94% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | NVCR | BEAM |
|---|---|---|
| 1Y ago | $8.5K (-15.0%) started 2025-06-18 | $20.09K (+100.9%) started 2025-06-18 |
| 5Y ago | $654.93 (-93.5%) started 2021-06-18 | $4.02K (-59.8%) started 2021-06-18 |
| 10Y ago | $12.24K (+22.4%) started 2016-06-20 | $18.21K (+82.1%) started 2020-02-06 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | NVCR | BEAM |
|---|---|---|
| Market cap | $1.65B | $3.51B |
| Trailing P/E | N/A | N/A |
| Forward P/E | -11.97 | -7.20 |
| Price/Sales | 2.45 | 21.42 |
| EV/Revenue | 2.71 | 12.95 |
| Analyst target | $26.00 | $51.07 |
| Target upside | +82.07% | +49.58% |
Growth, profitability & risk
| Metric | NVCR | BEAM |
|---|---|---|
| Revenue growth | 12.30% | 324.90% |
| Earnings growth | N/A | N/A |
| EPS growth | N/A | N/A |
| FCF margin | +0.75% | -142.40% |
| Operating margin | N/A | N/A |
| Profit margin | -25.66% | -40.23% |
| ROIC proxy | -49.96% | -5.77% |
| Return on equity | -49.96% | -5.77% |
| Dividend yield | 0.00% | 0.00% |
| Beta | 0.92 | 2.20 |
| Debt/equity | 71.04 | 21.54 |
| Current ratio | 2.90 | 16.99 |
| Quick ratio | 2.66 | 16.25 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
NVCR max drawdown45.67%
BEAM max drawdown38.15%
NVCR max wkly drop33.56%
BEAM max wkly drop16.62%
5Y risk snapshot
NVCR max drawdown95.55%
BEAM max drawdown89.12%
NVCR max wkly drop46.39%
BEAM max wkly drop31.25%
10Y risk snapshot
NVCR max drawdown95.55%
BEAM max drawdown89.12%
NVCR max wkly drop46.39%
BEAM max wkly drop41.11%
Performance metrics by period
| Period | Metric | NVCR | BEAM |
|---|---|---|---|
| 1Y | Growth | -15.00% | +100.94% |
| CAGR | -15.01% | +101.04% | |
| Sharpe ratio | 0.10 | 1.24 | |
| Max drawdown | 45.67% | 38.15% | |
| Max daily drop | 24.05% | 10.48% | |
| Max wkly drop | 33.56% | 16.62% | |
| 5Y | Growth | -93.45% | -59.84% |
| CAGR | -42.03% | -16.68% | |
| Sharpe ratio | -0.35 | 0.08 | |
| Max drawdown | 95.55% | 89.12% | |
| Max daily drop | 43.04% | 19.32% | |
| Max wkly drop | 46.39% | 31.25% | |
| 10Y | Growth | +22.37% | +82.08% |
| CAGR | +2.04% | +9.88% | |
| Sharpe ratio | 0.32 | 0.46 | |
| Max drawdown | 95.55% | 89.12% | |
| Max daily drop | 43.04% | 23.42% | |
| Max wkly drop | 46.39% | 41.11% |
Business comparison
| Category | NVCR | BEAM |
|---|---|---|
| Company | NovoCure Limited | Beam Therapeutics Inc. |
| Sector | Health Care - Medical Devices / Oncology | Health Care - Biotechnology / Gene Editing |
| Industry | N/A | N/A |
| Core business | NovoCure's Tumor Treating Fields (TTFields) technology delivers alternating electric fields to tumors using wearable devices, disrupting cancer cell division. It's commercially approved for glioblastoma (GBM) and mesothelioma, with clinical trials in lung cancer, pancreatic cancer, and other solid tumors. | Beam Therapeutics is developing base editing medicines — a next-generation gene editing approach that makes precise single-letter changes to DNA rather than causing double-strand cuts — for genetic blood diseases (sickle cell, beta-thalassemia) and liver diseases. |
| Investor focus | Investors track NovoCure's active patient count growth, net revenue per patient, payer coverage expansion (particularly commercial insurance in the U.S. and country approvals internationally), and the EF-32 lung cancer trial result as the most important pipeline catalyst. | Investors track Beam's clinical trial progress in hematological diseases (BEAM-101, BEAM-102), base editing safety and efficacy data, manufacturing platform development, and the company's cash position relative to its development timeline. |
NVCR strengths
- →Commercial revenue from two approved indications (GBM and MPM) provides a foundation while pipeline trials proceed in larger cancer indications
- →Lung cancer (EF-32 trial) represents a massive expansion opportunity — lung cancer is among the most common cancers globally with limited breakthrough therapies
- →TTFields mechanism is additive to chemotherapy, immunotherapy, and radiation — potential combinations multiply indication opportunities
BEAM strengths
- →Base editing technology makes more precise DNA edits than traditional CRISPR — changing individual DNA letters rather than cutting and rejoining, potentially reducing off-target editing risks
- →Sickle cell disease and beta-thalassemia are large, well-validated genetic disease targets where gene editing has shown dramatic clinical benefit
- →Proprietary base editing chemistry provides intellectual property foundation and potential for multiple disease applications
Risks to watch — NVCR
- →GBM is a rare cancer — the approved market size limits total addressable revenue without successful expansion into larger cancer indications
- →EF-32 lung cancer trial failure would be a major setback to the investment thesis centered on market expansion
- →Payer reimbursement challenges for TTFields outside the U.S. and Medicare GBM coverage slow international revenue growth
Risks to watch — BEAM
- →Base editing and CRISPR are pre-revenue biotechnology technologies — Beam has no approved products and uncertain commercialization timelines
- →Clinical trial safety data are critical — gene editing therapies must demonstrate no significant off-target editing effects
- →Competition from Vertex/CRISPR Therapeutics (Casgevy) and Bluebird Bio (Lyfgenia) which already have approved sickle cell therapies
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
More comparisons
Browse all 1,000 comparisons →